Trade United Therapeutics Corp - UTHR CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 1.06
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021568 %(-$0.43)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02157%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000654 %(-$0.01)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.01
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021568 %
  (-$0.43)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000654 %
  (-$0.01)

Key Stats

• Prev. Close: 487.5
• Open: 485.96
• 1-Year Change: 21.28%
• Day's Range: 485.96 - 504.08

Trade United Therapeutics Corp - UTHR

About United Therapeutics Corporation

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). It also includes technologies designed supply of transplantable organs and tissues and improves outcomes for transplant recipients through regenerative medicine, three-dimensional (3-D) organ bioprinting, xenotransplantation and ex-vivo lung perfusion.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, United Therapeutics Corporation revenues increased 14% to $1.69B. Net income decreased 8% to $475.8M. Revenues reflect Tyvaso segment increase of 26% to $607.5M, Unituxin segment increase of 65% to $202.3M, United States segment increase of 11% to $1.56B, Rest-of-World segment increase of 70% to $121.3M. Net income was offset by IPR&D asset impairment charges increase from $0K to $113.4M (expense).

Equity composition

Common Stock $.01 Par, 06/11, 245M auth., 60,817,983 issd., less 2,503,657 shs. in Treas. @ $70.1M. Insiders control 1.10%. IPO: 6/17/99, 4,500,000 @ $12 by Deutsche Banc Alex. Brown. 09/09, 2-for-1 stock split.